Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in GPCR-focused therapeutic proteins and antibodies, has announced its participation in three major healthcare investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference on September 3 for investor meetings, the Cantor Global Healthcare Conference on September 4 featuring a fireside chat with CFO Daniel Lochner and CBO Marc Schwabish, and the Morgan Stanley Global Healthcare Conference on September 10 with CEO Alise Reicin. Both fireside chats will be webcast and available for replay on the company's website.
Tectonic Therapeutic (NASDAQ: TECX), una società biofarmaceutica in fase clinica specializzata in proteine terapeutiche e anticorpi focalizzati sui recettori accoppiati a proteine G (GPCR), ha annunciato la propria partecipazione a tre importanti conferenze per investitori nel settore sanitario a settembre 2025.
L'azienda sarà presente al Wells Fargo Healthcare Conference il 3 settembre per incontri con investitori, al Cantor Global Healthcare Conference il 4 settembre con un fireside chat a cui parteciperanno il CFO Daniel Lochner e il CBO Marc Schwabish, e al Morgan Stanley Global Healthcare Conference il 10 settembre con la CEO Alise Reicin. Entrambi i fireside chat saranno trasmessi in webcast e disponibili in replay sul sito web della società.
Tectonic Therapeutic (NASDAQ: TECX), una compañía biotecnológica en fase clínica especializada en proteínas terapéuticas y anticuerpos dirigidos a GPCR, ha anunciado su participación en tres importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La compañía asistirá al Wells Fargo Healthcare Conference el 3 de septiembre para reuniones con inversores, al Cantor Global Healthcare Conference el 4 de septiembre, donde habrá un fireside chat con el CFO Daniel Lochner y el CBO Marc Schwabish, y al Morgan Stanley Global Healthcare Conference el 10 de septiembre con la CEO Alise Reicin. Ambos fireside chats se emitirán por webcast y estarán disponibles en reproducción en la web de la compañía.
Tectonic Therapeutic (NASDAQ: TECX)는 GPCR을 표적으로 하는 치료용 단백질 및 항체를 전문으로 하는 임상 단계의 바이오테크 기업으로, 2025년 9월에 개최되는 주요 헬스케어 투자자 콘퍼런스 세 곳에 참가할 예정이라고 발표했습니다.
회사는 9월 3일 Wells Fargo Healthcare Conference에서 투자자 미팅을 진행하고, 9월 4일 Cantor Global Healthcare Conference에서는 CFO 다니엘 로흐너(Daniel Lochner)와 CBO 마크 슈와비시(Marc Schwabish)의 파이어사이드 채트(fireside chat)가 열리며, 9월 10일 Morgan Stanley Global Healthcare Conference에서는 CEO 알리스 레이신(Alise Reicin)이 참석합니다. 두 차례의 파이어사이드 채트는 웹캐스트로 중계되며 회사 웹사이트에서 다시보기가 가능합니다.
Tectonic Therapeutic (NASDAQ: TECX), une société de biotechnologie en phase clinique spécialisée dans les protéines thérapeutiques et les anticorps ciblant les GPCR, a annoncé sa participation à trois grandes conférences destinées aux investisseurs dans le secteur de la santé en septembre 2025.
L'entreprise assistera au Wells Fargo Healthcare Conference le 3 septembre pour des réunions avec des investisseurs, au Cantor Global Healthcare Conference le 4 septembre avec une discussion en table ronde (« fireside chat ») réunissant le CFO Daniel Lochner et le CBO Marc Schwabish, et au Morgan Stanley Global Healthcare Conference le 10 septembre avec la CEO Alise Reicin. Les deux sessions en table ronde seront diffusées en webcast et disponibles en replay sur le site web de la société.
Tectonic Therapeutic (NASDAQ: TECX), ein Biotechnologieunternehmen in der klinischen Phase, das sich auf GPCR-gerichtete therapeutische Proteine und Antikörper spezialisiert hat, hat seine Teilnahme an drei bedeutenden Healthcare-Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 3. September auf der Wells Fargo Healthcare Conference für Investorenmeetings vertreten sein, am 4. September auf der Cantor Global Healthcare Conference mit einem Fireside-Chat, an dem CFO Daniel Lochner und CBO Marc Schwabish teilnehmen, und am 10. September auf der Morgan Stanley Global Healthcare Conference mit CEO Alise Reicin. Beide Fireside-Chats werden per Webcast übertragen und sind auf der Website des Unternehmens als Wiederholung verfügbar.
- None.
- None.
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025.
2025 Wells Fargo Healthcare Conference
| Date: | September 3, 2025 |
| Location: | Boston, MA |
| Format: | Investor Meetings |
Cantor Global Healthcare Conference
| Date: | September 4, 2025 |
| Time: | 2:10 PM EDT |
| Location: | New York, NY |
| Format: | Fireside Chat |
| Presenters: | Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer |
| Webcast: | Link |
Morgan Stanley 23rd Annual Global Healthcare Conference
| Date: | September 10, 2025 |
| Time: | 3:20 PM EDT |
| Location: | New York, NY |
| Format: | Fireside Chat |
| Presenter: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
Both live fireside chats can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.
The Tectonic management team will host one-on-one meetings during the three conferences. Interested investors should contact their Wells Fargo, Cantor, and Morgan Stanley representatives to schedule meetings.
About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.
Contacts: Investors: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com Media: Kathryn Morris The Yates Network (914) 204-6412 kathryn@theyatesnetwork.com
FAQ
When is Tectonic Therapeutic (TECX) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent Tectonic Therapeutic at the Morgan Stanley Healthcare Conference 2025?
Where can investors access Tectonic Therapeutic's (TECX) conference presentations?
How can investors schedule meetings with Tectonic Therapeutic management at these conferences?
